Effectiveness of Topical Sucralfate in the Management of Pressure Ulcer in Hospitalized Patients: A Prospective, Randomized, Placebo-Controlled Trial

被引:8
作者
Ala, Shahram [1 ]
Saeedi, Majid [2 ]
Gholipour, Afshin [3 ]
Ahmadi, Motahareh [1 ]
Asoodeh, Ali [4 ]
Shiva, Afshin [1 ,5 ]
机构
[1] Mazandaran Univ Med Sci, Fac Pharm, Dept Clin Pharm, Sari, Mazandaran Prov, Iran
[2] Mazandaran Univ Med Sci, Fac Pharm, Dept Pharmaceut, Sari, Mazandaran Prov, Iran
[3] Mazandaran Univ Med Sci, Dept Anaesthesiol, Sari 48175861, Mazandaran Prov, Iran
[4] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Intens Care Unit, Sari, Mazandaran Prov, Iran
[5] Urmia Univ Med Sci, Fac Pharm, Dept Clin Pharm, Orumiyeh, Iran
关键词
pressure ulcer; sucralfate; randomized trial; healing; PUSH score; DOUBLE-BLIND; ANAL FISTULOTOMY; PREVENTION; OINTMENT; EFFICACY; CREAM; HEMORRHOIDECTOMY; COLLAGENASE; PAIN;
D O I
10.1097/MJT.0000000000000531
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The aim of this study was to evaluate the effectiveness of topical sucralfate in the management of pressure ulcer (PU) in hospitalized patients. Methods: Forty hospitalized patients with stage II PU were included in this prospective, doubleblind, randomized, placebo-controlled trial and were randomly divided into 2 groups receiving either sucralfate gel or placebo, on a daily basis. The patients were visited every day for 14 days, the ulcer was evaluated using the Pressure Ulcer Scale for Healing (PUSH) and changes to the measured scores over time were used as an indicator of wound healing. Results: There were no statistically significant differences in any of the demographic characteristics between both groups. Both of the interventions reduced the average PUSH score, and at the end of the trial, all but 2 patients were healed. One in each group discontinued the trial because of exacerbation of the ulcer. No significant between-group difference in the average PUSH score reduction was observed (6.36 6 2.11 vs. 5.89 6 1.41, P 5 0.42). Although the average healing time was less in the sucralfate group (6.05 6 2.17 vs. 7.78 6 3.42), the difference was not statistically significant (P 5 0.07). Conclusions: Sucralfate gel does not improve healing of PU compared with placebo.
引用
收藏
页码:E5 / E11
页数:7
相关论文
共 40 条
[1]   Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial [J].
Ala, Shahram ;
Saeedi, Majid ;
Janbabai, Ghasem ;
Ganji, Reza ;
Azhdari, Elham ;
Shiva, Afshin .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2016, 68 (03) :456-463
[2]   Efficacy of 10 % Sucralfate Ointment in the Reduction of Acute Postoperative Pain After Open Hemorrhoidectomy: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial [J].
Ala, Shahram ;
Saeedi, Majid ;
Eshghi, Fariborz ;
Rafati, Mohamadreza ;
Hejazi, Vahid ;
Hadianamrei, Roja .
WORLD JOURNAL OF SURGERY, 2013, 37 (01) :233-238
[3]   Efficacy of 10% sucralfate ointment after anal fistulotomy: A prospective, double-blind, randomized, placebo-controlled trial [J].
Alvandipour, Mina ;
Ala, Shahram ;
Tavakoli, Hasan ;
Charati, Jamshid Yazdani ;
Shiva, Afshin .
INTERNATIONAL JOURNAL OF SURGERY, 2016, 36 :13-17
[4]  
Amin MR, 2014, CHATT SHI HOSP MED C, V13, P12
[5]  
[Anonymous], 2008, US PHARM
[6]   Topical use of Sucralfate Cream in second and third degree burns [J].
Banati, A ;
Chowdhury, SR ;
Mazumder, S .
BURNS, 2001, 27 (05) :465-469
[7]  
Black Joyce, 2007, Adv Skin Wound Care, V20, P269, DOI 10.1097/01.ASW.0000269314.23015.e9
[8]   SUCRALFATE INDUCES PROLIFERATION OF DERMAL FIBROBLASTS AND KERATINOCYTES IN CULTURE AND GRANULATION-TISSUE FORMATION IN FULL-THICKNESS SKIN WOUNDS [J].
BURCH, RM ;
MCMILLAN, BA .
AGENTS AND ACTIONS, 1991, 34 (1-2) :229-231
[9]   Collagenase ointment application at 24-versus 48-hour intervals in the treatment of pressure ulcers -: A randomised multicentre study [J].
Burgos, A ;
Giménez, J ;
Moreno, E ;
Campos, J ;
Ardanaz, J ;
Talaero, C ;
Sanz, M ;
García, J ;
Benito, S ;
Pastor, S ;
Hernández, C ;
Ballesteros, E ;
Rivera, C .
CLINICAL DRUG INVESTIGATION, 2000, 19 (06) :399-407
[10]  
Candelli M, 2000, PANMINERVA MED, V42, P55